# DDI HV (ATV - Merck)

> **NCT00518297** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 22 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Raltegravir
- **DRUG:** Atazanavir
- **DRUG:** Atazanavir + Raltegravir

## Key facts

- **NCT ID:** NCT00518297
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2010-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00518297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00518297, "DDI HV (ATV - Merck)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00518297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*